Cargando…

Lymphocyte Exhaustion in AML Patients and Impacts of HMA/Venetoclax or Intensive Chemotherapy on Their Biology

SIMPLE SUMMARY: Patients with acute myeloid leukemia (AML) are routinely treated with either intensive chemotherapy or DNA hypomethylating agents (HMA) in combination with the Bcl-2 inhibitor, venetoclax. While both treatment regimens are highly cytotoxic to the aggressive AML tumor cells, they are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhigarev, Dmitry, Varshavsky, Asya, MacFarlane, Alexander W., Jayaguru, Prathiba, Barreyro, Laura, Khoreva, Marina, Dulaimi, Essel, Nejati, Reza, Drenberg, Christina, Campbell, Kerry S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320805/ https://www.ncbi.nlm.nih.gov/pubmed/35884414 http://dx.doi.org/10.3390/cancers14143352

Ejemplares similares

AML-337: Targeting E-Selectin with GMI-1271 Overcomes Microenvironment-Mediated Resistance to Venetoclax/HMA Therapy
por: Chang, Kyung Hee, et al.
Publicado: (2020)

Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA
por: Watts, Justin, et al.
Publicado: (2022)

Review of Venetoclax in CLL, AML and Multiple Myeloma
por: Lasica, Masa, et al.
Publicado: (2021)

Augmenting Venetoclax Activity Through Signal Transduction in AML
por: Bouligny, Ian Michael, et al.
Publicado: (2023)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
por: Bernardi, Massimo, et al.
Publicado: (2022)

P525: LONG-TERM OUTCOMES OF STEM CELL TRANSPLANT IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX + HMA THERAPIES
por: Pratz, Keith, et al.
Publicado: (2023)

HMA6 and HMA8 are two chloroplast Cu(+)-ATPases with different enzymatic properties
por: Sautron, Emeline, et al.
Publicado: (2015)

Expression of HMA4 cDNAs of the zinc hyperaccumulator Noccaea caerulescens from endogenous NcHMA4 promoters does not complement the zinc-deficiency phenotype of the Arabidopsis thaliana hma2hma4 double mutant
por: Iqbal, Mazhar, et al.
Publicado: (2013)

Determination the Usefulness of AhHMA4p1::AhHMA4 Expression in Biofortification Strategies
por: Weremczuk, Aleksandra, et al.
Publicado: (2016)

Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma
por: Pazina, Tatiana, et al.
Publicado: (2021)

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
por: Jasra, Sakshi, et al.
Publicado: (2021)

FOXM1-AKT Positive Regulation Loop Provides Venetoclax Resistance in AML
por: Chesnokov, Mikhail S, et al.
Publicado: (2021)

P555: OLUTASIDENIB IN POST-VENETOCLAX PATIENTS WITH MUTANT IDH1 AML
por: Cortes, Jorge, et al.
Publicado: (2023)

Functional Significance of AtHMA4 C-Terminal Domain In Planta
por: Mills, Rebecca F., et al.
Publicado: (2010)

Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies
por: Stomper, Julia, et al.
Publicado: (2021)

Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine
por: Zhang, Lei-Si, et al.
Publicado: (2022)

AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax
por: Low, Soon Khai, et al.
Publicado: (2022)

Effective reduction of cadmium accumulation in rice grain by expressing OsHMA3 under the control of the OsHMA2 promoter
por: Shao, Ji Feng, et al.
Publicado: (2018)

Downregulation of CD73 associates with T cell exhaustion in AML patients
por: Kong, Yaxian, et al.
Publicado: (2019)

Structural Insights into the Nucleotide-Binding Domains of the P(1B)-type ATPases HMA6 and HMA8 from Arabidopsis thaliana
por: Mayerhofer, Hubert, et al.
Publicado: (2016)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
por: Joshi, Maansi, et al.
Publicado: (2021)

Durable response of therapy-related MDS/AML with concomitant Waldenström’s macroglobulinemia treated with venetoclax and azacitidine
por: Hirano, Mitsuhito, et al.
Publicado: (2022)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
por: Jin, Hua, et al.
Publicado: (2023)

P488: SAFETY AND EFFICACY OF VENETOCLAX PLUS “7 + 3” CHEMOTHERAPY IN NEWLY DIAGNOSED AML
por: Mantzaris, Ioannis, et al.
Publicado: (2023)

P564: HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML
por: Luo, Xiao-Hua, et al.
Publicado: (2023)

di-Cysteine motifs in the C-terminus of plant HMA4 proteins confer nanomolar affinity for zinc and are essential for HMA4 function in vivo
por: Lekeux, Gilles, et al.
Publicado: (2018)

Genome-wide identification of ZmHMAs and association of natural variation in ZmHMA2 and ZmHMA3 with leaf cadmium accumulation in maize
por: Cao, Yanhua, et al.
Publicado: (2019)

The activity of the RGA5 sensor NLR from rice requires binding of its integrated HMA domain to effectors but not HMA domain self‐interaction
por: Xi, Yuxuan, et al.
Publicado: (2022)

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
por: Garcia, Jacqueline S., et al.
Publicado: (2021)

Synergy of Venetoclax and 8-Chloro-Adenosine in AML: The Interplay of rRNA Inhibition and Fatty Acid Metabolism
por: Hoang, Dinh Hoa, et al.
Publicado: (2022)

Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation
por: Hoang, Dinh Hoa, et al.
Publicado: (2022)

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis
por: Hurrish, Katie H., et al.
Publicado: (2023)

AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens
por: Milnerowicz, Szymon, et al.
Publicado: (2023)

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
por: Daver, Naval G., et al.
Publicado: (2023)

Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML: a multicenter retrospective analysis
por: Masetti, Riccardo, et al.
Publicado: (2023)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
por: Cao, Xing-yu, et al.
Publicado: (2023)

Predicting the HMA-LMA Status in Marine Sponges by Machine Learning
por: Moitinho-Silva, Lucas, et al.
Publicado: (2017)

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM
por: Huemer, Florian, et al.
Publicado: (2019)

Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis
por: Vazquez, Romain, et al.
Publicado: (2021)

Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax
por: Candoni, Anna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9v1vb25tkd1astqginrqnjuib2